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Abstract 
Background: Cancer fear has been associated with higher and lower screening uptake 
across different studies, possibly because different aspects of cancer fear have different 
effects on intentions versus behaviour.  The present study examined associations of three 
aspects of cancer fear with intention and uptake of endoscopic screening for colorectal 
cancer. 
Methods:  A sub-sample of UK Flexible Sigmoidoscopy (FS) Trial participants received a 
baseline questionnaire that included three cancer fear items from a standard measure 
asking if: i) cancer was feared more than other diseases, ii) cancer worry was experienced 
frequently, and iii) thoughts about cancer caused discomfort.  Screening intention was 
assessed by asking participants whether, if invited, they would accept an invitation for FS 
screening.  Positive responders were randomised to be invited or not in a 1:2 ratio.  The 
behavioural outcome was clinic-recorded uptake.  Control variables were age, gender, 
ethnicity, education, and marital status. 
Results:  The questionnaire return rate was 60% (7,971/13,351).  The majority (82%) 
intended to attend screening; 1,920 were randomised to receive an invitation, and 71% 
attended.  Fearing cancer more than other diseases (OR=2.32, p<.01) and worrying a lot 
about cancer (OR=2.34, p<.01) increased intentions to attend screening, but not uptake.  
Finding thoughts about cancer uncomfortable did not influence intention, but predicted lower 
uptake (OR=0.72, p<.01). 
Conclusions:  Different aspects of cancer fear have different effects on the decision and 
action processes leading to screening participation.   
Impact: Knowledge of the different behavioural effects of cancer fear may aid the design of 
effective public health messages. 
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Introduction 
Cancer fear has been implicated both as a facilitator and a deterrent to screening uptake.  A 
meta-analysis of twelve prospective studies in breast cancer found a linear relationship 
between cancer fear and screening uptake (1).  However, two studies examining colorectal 
screening uptake found no association with fear (2, 3), while other studies of breast 
screening (4-7), and of prostate (4) and ovarian cancer screening (8), found a curvilinear 
relationship; with both low and high fear associated with lower uptake.   
 
One possible explanation for the varying results could be that the studies used different 
measures of cancer fear, and the effects on screening participation could vary depending on 
the aspect of fear examined (9, 10).  Fear is best understood as a multi-dimensional 
construct, with loosely-coupled cognitive, biological, affective and behavioural components 
(11).  Fear of cancer has been operationalised in many ways, for example: ‘worry about 
cancer’, ‘cancer-related distress’, ‘intrusive and avoidant thoughts about cancer’, and ‘effects 
of cancer-related thoughts on mood and daily activities’ (9).  Cancer worry could promote 
screening uptake as a means of seeking reassurance, at least among individuals who 
perceive their risk as low, while avoidant or fatalistic views may be a deterrent to screening 
(6, 9, 10).  The observed effect in any individual study could depend on the specific fear 
indicator used.    
 
Several studies have used multiple item scales covering several different aspects of cancer 
fear, but have usually combined them into a single fear score to predict behaviour, making it 
difficult to assess the independent effect of individual fear components (e.g. 5, 12).  
However, in two studies, one of breast and one of prostate cancer, cancer worry was 
associated with a stronger intention to obtain screening and more frequent screening, 
whereas fear about screening itself and its results was associated with lower intention and 
less frequent screening (13, 14).  Wong et al. (15) found similar relationships for colorectal 
cancer (CRC) in a sample of older adults in Singapore: worry was associated with higher 
uptake, while fear of cancer being found during screening was associated with lower uptake.  
A similar pattern emerged in a sample of low income Hispanic Americans (16):   levels of 
cancer worry were higher among those who had received colonoscopy screening, while 
levels of fatalism were (non-significantly) higher among those who had not been screened.   
 
No study has explicitly tested the relative contributions of cognitive, biological, and affective 
components of fear on screening participation.  We therefore used prospective data from the 
UK Flexible Sigmoidoscopy (FS) Trial to examine the association between these three 
aspects of cancer fear and two indices of participation: intention and uptake of screening for 
colorectal cancer. 
   
Materials and methods 
Design 
Data for this secondary analysis come from a sub-sample of participants (n=13,351) in the 
UK Flexible Sigmoidoscopy (FS) Trial who had been sent an extended baseline 
questionnaire prior to their screening invitation.  Data were collected between 1996 and 
1999.  The UK FS Trial is a multi-centre randomised controlled trial assessing the effect of 
once-only FS screening in adults aged 55-64 years on CRC incidence and mortality (17, 18).  
It used a two-step recruitment process to increase statistical power in intention-to-treat 
analyses.  Potential participants (n=375,744) were all adults aged 55-64 years in 506 
participating General Practices (GP) across the UK.  After exclusions by GPs, 368,142 
participants were sent information about the Trial, together with a baseline questionnaire 
asking about intention to attend FS screening (‘If you were invited to have the bowel cancer 
screening test, would you take up the offer: yes definitely, yes probably, probably not, 
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definitely not’).  Those who answered ‘yes probably’ or ‘yes definitely’ were randomised in a 
1:2 ratio to receive an invitation for FS screening or care-as-usual, as per the Trial protocol 
(17).  Ethics approval was obtained from the local research ethics committee for all 
participating centres. 
 
Participants 
Participants (n=13,351) in a sub-sample of Practices were randomly selected to take part in 
a psychological sub-study of the main FS trial.  These participants received a longer version 
of the baseline questionnaire that included items on cancer fear, demographics, health, and 
psychosocial measures.  Our sample for analyses of associations between cancer fear and 
screening intention consisted of this sub-sample (Sample 1).  Among those who responded 
that they would ‘probably’ or ‘definitely’ take up the offer of screening, and were therefore 
entered into the randomisation schedule, 1,995 were randomised to receive a screening 
invitation.  This constituted our sample for analyses of screening uptake (Sample 2).  All 
participants were naïve to CRC screening, which was not part of the UK National Cancer 
Screening Programme at the time of the study. 
 
Screening intention and uptake 
Screening intention was based on the questionnaire responses described above (Sample 1).  
For the analyses of associations between fear and screening intention, responses to the 
screening intention question were dichotomised (yes definitely/yes probably vs. probably 
not/definitely not).  Screening uptake was recorded in the clinic (attended vs. did not attend) 
for all participants randomised to be sent a screening invitation (Sample 2).  Clinic records of 
screening attendance for those who were invited were 100% complete.   
 
Cancer fear 
Three aspects of cancer fear were assessed in the baseline questionnaire, each with a 
single item statement.  One item reflected a more cognitive evaluation of cancer fear (‘Of all 
the diseases there are, I am most afraid of cancer’), one reflected a more affective response 
to cancer (‘I worry a lot about cancer’), and one was more psychobiological (‘It makes me 
uncomfortable to think about cancer’).  Responses were on 5 point scales: ‘strongly 
disagree’, ‘disagree’, ‘not sure’, ‘agree’, and ‘strongly agree’.  We combined the ‘agree’ and 
‘strongly agree’ categories for the multivariate logistic regression analyses examining the 
associations of fear with screening interest and uptake, because we were interested in the 
effect of the presence of cancer fear.  We combined the ‘strongly disagree’ and ‘disagree’ 
categories to create a robust reference group of people without cancer fear, because 
numbers for the ‘strongly disagree’ category were small.  ‘Not sure’ was treated as the mid-
point because it was physically placed between ‘agree’ and ‘disagree’ on the response scale 
on the questionnaire, but we did sensitivity analyses excluding respondents with ‘not sure’ 
responses.  
 
Sociodemographic control variables 
Demographic data included age, gender, ethnicity, educational qualifications, and marital 
status.  Age and gender were taken from GP records.  Ethnicity was assessed with the 
question ‘which of these best describes your ethnic background’, with response categories 
‘White’, ‘Black’, ‘Asian’, ‘Other’, ‘Do not wish to answer’.  Numbers for ‘Black’ (n=99), ‘Asian’ 
(n=183), and ‘Other’ (n=43) were small, and therefore combined in a ‘non-White’ category.  
‘Do not wish to answer’ was coded as missing.  A single item was used to record education: 
‘do you have any educational qualifications’ (e.g. School Certificate, GCE O’Levels, etc.), 
with ‘yes’ or ‘no’ response options.  In this cohort, born between 1932 and 1943, continuation 
in education would have depended on passing these examinations taken at age 16.  
Education is a good index of socioeconomic status (SES) in older adults (19).  Marital status 
was assessed with ‘what is your marital status’, with response categories dichotomised into 
‘married or cohabiting’ and ‘not married or cohabiting’.  For all demographics, missing data 
were coded as a separate category. 
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Statistical analysis 
Percentages of respondents intending to attend (Sample 1), and attending (Sample 2), were 
analysed in relation to each fear indicator.  Multivariate logistic regression analyses for each 
cancer fear indicator individually were used to examine associations with screening intention 
(Sample 1) and uptake (Sample 2), using the dichotomised variables for screening intention 
and uptake, and adjusting for differences in sociodemographic characteristics.  ‘Not sure’ 
was used as mid-point for the cancer fear indicators in these analyses, but a sensitivity 
analysis was performed in which this category was coded as missing.  We also conducted a 
sensitivity analysis with all categories for the fear items.  Bonferroni corrections were applied 
to control for the family-wise error rate due to multiple comparisons, and a p-value of .01 was 
used to indicate statistical significance.  SPSS version 22.0 was used for all analyses. 
 
Results 
Return rate of the extended baseline questionnaire was 60% (7,971/13,351).  Almost all 
respondents (98%; n=7,780) had a valid response on the screening intention question, and 
91% (n=7,327) had complete data on all three cancer fear indicators; this constituted 
Sample 1.  Of this group, 82% intended to take up the offer of screening if invited; with 53% 
saying they would probably attend and 29% that they would definitely attend.  A flow 
diagram of the inclusion process is presented in Figure 1.Among those who said they would 
either probably or definitely attend (6,299/7,780), 1,995 were randomised to receive a 
screening invitation as per the Trial protocol.  The majority (96%; 1,920/1,995) had complete 
data on all three cancer fear indicators; this constituted Sample 2.  Of this group, 71% 
(1,359/1,920) attended.  Those who had responded ‘definitely’ were more likely to attend 
than those who responded ‘probably’ (80% vs. 54%). 
 
Cancer fear and screening intention 
The first set of analyses examined associations between each fear item and intention to 
attend in Sample 1 (n=7,327; see Table 1).  There were slightly more women (54%) than 
men (46%) in this sample.  More than half (60%) did not have any educational qualifications, 
the majority (93%) were from a White ethnic background, and 73% were married or 
cohabiting.   
 
Overall, 59% of respondents agreed or strongly agreed that they were more afraid of cancer 
than other diseases, 53% agreed or strongly agreed that they felt uncomfortable thinking 
about cancer, and 25% agreed or strongly agreed that they worried a lot about cancer.  As 
previously reported in this sample (20), Spearman’s correlations between the cancer fear 
items (before the extreme categories were grouped together) were modest: between .36 and 
.42 (Table 2).  This suggests that there is some commonality between these indicators of 
cancer fear but that they also tap into different aspects (20). 
 
More respondents who reported having cancer as their greatest health fear said they 
intended to attend screening: 86% vs. 79% of those who were not sure, and 74% of those 
who disagreed (see Table 3).  The same relationship was observed for cancer worry: 89% of 
those who worried about cancer a lot intended to attend, compared with 83% of those who 
were unsure, and 79% of those who did not worry about cancer.  However, the pattern was 
different for feeling uncomfortable thinking about cancer: 80% intended to attend among 
those who agreed with this item, vs. 85% of those who were unsure, and 83% of those who 
did not agree. 
 
Adjusted logistic regression analyses controlling for age, gender, education, ethnicity, and 
marital status are shown in Table 3.  Having cancer as greatest health fear or worrying about 
cancer a lot were associated with greater screening intention.  Discomfort when thinking 
about cancer did not affect intention to attend screening.  Sensitivity analyses in which the 
‘not sure’ category was coded as missing showed the same pattern: having cancer as the 
greatest health fear and worrying about cancer a lot were associated with an increased 
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likelihood to intend to attend screening.  Discomfort did not affect screening intention (results 
not shown).  We also repeated the analysis with all the fear categories.  The results showed 
a similar pattern in terms of associations with screening intentions (results not shown); we 
chose to report the results for the largest sample size.  
 
Cancer fear and screening uptake 
The second set of analyses examined uptake among the group who had said they intended 
to attend screening and were randomised to be invited (Sample 2).  There were slightly more 
women (52%) than men (48%) in this sample, the majority (58%) did not have any 
educational qualifications, most (93%) were of White ethnic background, and most (75%) 
were married or cohabiting (see Table 1).   
 
In this group, more than half (64%) agreed or strongly agreed that they were more afraid of 
cancer than other diseases, 52% felt uncomfortable thinking about cancer, and 28% worried 
a lot about cancer.  The higher percentages of having cancer as the greatest health fear and 
cancer worry than in Sample 1, and the slightly lower percentage of discomfort thinking 
about cancer, reflect the associations between these variables and screening intention. 
 
In terms of percentages attending, those who reported higher fear on any of the three fear 
indicators were slightly less likely to actually take part in screening (Table 4).  Of those who 
reported that cancer was their greatest health fear, 70% attended FS screening, compared 
with 72% for whom it was not.  For cancer worry, 65% of those who reported worrying a lot 
attended screening, vs. 72% of those who did not worry about cancer.  For discomfort 
thinking about cancer, 68% of those who felt uncomfortable attended screening, vs. 77% of 
those who did not feel uncomfortable.   
 
In adjusted logistic regression analyses controlling for age, gender, education, ethnicity, and 
marital status (see Table 4), only discomfort thinking about cancer had a significant deterrent 
effect on screening uptake in those who had previously indicated that they intended to 
attend (OR 0.72 [0.56-0.91], p<.01).  We conducted a sensitivity analysis in which the ‘not 
sure’ category was coded as missing; this showed the same pattern of results (results not 
shown).  A second sensitivity analysis using all categories for the three cancer fear variables 
also showed a similar relationship between cancer fear and screening uptake.  We therefore 
reported the analysis with the largest sample size. 
 
Discussion 
This is the largest study to date to have recorded information on cancer fear before a 
screening invitation was offered, to have clinic records of uptake as well as reported 
intention, and to explicitly compare different aspects of cancer fear.  In terms of screening 
intention, we found evidence that the cognitive/affective aspects of cancer fear (cancer as 
greatest health fear, worry about cancer) were significant facilitators of screening intention, 
while the more psychobiological aspect (discomfort thinking about cancer) was not 
significantly related to screening intention.  Once those who were interested in screening 
were invited, the cognitive/affective aspects of cancer fear did not have any residual effect 
on actual behaviour (screening uptake).  In contrast, discomfort thinking about cancer, which 
had not affected intention, was a deterrent to taking part in cancer screening in this sample 
who had already indicated an intention to attend.  
 
These findings lend support to the idea that different aspects of cancer fear may have 
different behavioural effects, but also that they may exert their effects at different stages in 
the decisional process.  In line with results from earlier studies (13, 15, 16), we found that 
cancer worry facilitated screening through enhancing intention to attend  – perhaps 
motivated by a desire for reassurance, while a more visceral negative response to thinking 
about a cancer acted as a deterrent at the action stage.  The distinction between influences 
on intention and action are an important emerging area of work in helping to understand the 
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‘intention-behaviour gap’ (21).  Although the behavioural effects of these three aspects of 
cancer fear may be different, a previous study has shown that their sociodemographic 
correlates are largely similar, with women, and those without educational qualifications and 
from ethnic minority backgrounds most affected (20).  In addition to the different ways in 
which cancer fear is experienced (i.e. as worry, distress, intrusive thoughts, etc.), some 
authors have noted that there may also be individual differences in the object of cancer fear 
and the associated behavioural effects (e.g. fear of a cancer diagnosis, fear of dying from 
cancer, etc.; see for example, 10), although these distinctions were beyond the scope of the 
present study.   
 
Some cross-sectional studies have assessed the effects of cancer fear by using past 
screening uptake as the outcome (e.g. 4, 5, 8).  The disadvantage of this approach is that 
past screening results may influence subsequent cancer fear; a problem known as ‘reverse 
causality’ (9).  The present study avoids the problem of reverse causality because cancer 
fear was measured in a screening naïve sample before any screening invitation.  It thus 
contributes to our understanding of the influence of different aspects of cancer fear on 
intentions and behaviour, and also stresses the importance of measuring behaviour (and not 
only intentions) when assessing health behaviours.   
 
One limitation of the present study was that data about cancer fear and screening interest 
were collected at the same time, meaning that the possibility of reverse causality remains an 
issue for the associations between cancer fear and screening interest.  This causal direction 
can only be established through further longitudinal or interventional studies. 
 
Our study also had other limitations.  Response rate to the baseline questionnaire (60%) 
was good for a community-based survey, but still meant we had no information on intentions 
on the 40% of non-responders.  Participants could see that the questionnaire was about 
cancer and those with higher levels of cancer fear may have been less likely to return it.  If 
cancer fear is a cause of non-response, then the high proportions of those endorsing the 
fear statements would in fact be an underrepresentation of the prevalence of cancer fear in 
older adults. The cancer fear measures that were used were not specific to CRC.  Although 
many previous studies have used specific CRC fear measures to determine the effect on 
intentions and uptake of screening (e.g. 2, 22), we had chosen more general measures 
because they may better reflect cancer fear as experienced by the general population (i.e. 
as a non-specific “fear of cancer”, rather than a specific “fear of CRC”), and because they 
allow for future comparisons of the behavioural effects of these aspects of cancer fear 
across different types of cancer screening.  In addition, we used single item measures.  
However, the moderate correlation between the items, the different endorsement rates, and 
the differential relationships with screening interest and uptake support the idea that the 
items represent different aspects of cancer fear that may need to be distinguished if we seek 
to understand the behavioural effects of cancer fear (9, 10).   
 
The trial design imposed limitations because it specified only inviting respondents who 
expressed some interest in attending. We therefore do not know how many ‘non-intenders’ 
might actually have attended if they had received an invitation, nor whether the associations 
between cancer fear and screening uptake would have been similar in this group.  Future 
studies that invite all potential participants to take part in screening – regardless of screening 
intentions - would reduce any bias that may have been introduced by the sampling method 
used in the current study.  Finally, in the questionnaire, ‘not sure’ was presented as the 
midpoint of the response scale for the cancer fear indicators, between disagree and agree.  
This category was also used as the midpoint for the analyses.  However, some participants 
may have interpreted this response option as ‘don’t know’, rather than as midpoint of an 
agreement scale, as demonstrated by others (23).  We therefore carried out sensitivity 
analyses omitting respondents who endorsed ‘not sure’, which did not change the broad 
pattern of results.   
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Conclusions 
The results of this study confirm that cancer fear can be a facilitator or a deterrent, 
depending on the specific aspect of fear.  Having cancer as the greatest health fear or 
worrying a lot about cancer facilitated intentions to attend, while finding thoughts of cancer 
uncomfortable did not affect intention but was a deterrent to actual uptake.  Learning more 
about the make-up of cancer fear, and having more nuanced analyses of the behavioural 
effects, might help in the design of effective public health messages.   
 
Acknowledgements 
We would like to thank Professor Wendy Atkin (Principal Investigator for the UK Flexible 
Sigmoidoscopy Trial) for letting us use data from the UK Flexible Sigmoidoscopy Trial for the 
current study.  The UK FS Trial was funded by the Medical Research Council, National 
Health Service R&D, Cancer Research UK, and KeyMed. 
 
References 
1. Hay JL, McCaul KD, Magnan RE. Does worry about breast cancer predict screening 
behaviors? A meta-analysis of the prospective evidence. Prev Med 2006;42:401-8. 
2. Llanos AA, Pennell ML, Young GS, Tatum CM, Katz ML, Paskett ED. No association 
between colorectal cancer worry and screening uptake in Appalachian Ohio. J Public 
Health;2014 (in press). 
3. Moser RP, McCaul K, Peters E, Nelson W, Marcus SE. Associations of perceived 
risk and worry with cancer health-protective actions data from the Health Information 
National Trends Survey (HINTS). J Health Psychol 2007;12:53-65. 
4. Consedine NS, Morgenstern AH, Kudadjie-Gyamfi E, Magai C, Neugut AI. Prostate 
cancer screening behavior in men from seven ethnic groups: the fear factor. Cancer 
Epidemiol Biomarkers  Prev 2006;15:228-37. 
5. Andersen MR, Smith R, Meischke H, Bowen D, Urban N. Breast cancer worry and 
mammography use by women with and without a family history in a population-based 
sample. Cancer Epidemiol Biomarkers Prev 2003;12:314-20. 
6. Champion VL, Skinner CS, Menon U, Rawl S, Giesler RB, Monahan P, et al. A 
breast cancer fear scale: psychometric development. J Health Psychol 2004;9:753-62. 
7. Sutton S, Bickler G, Sancho-Aldridge J, Saidi G. Prospective study of predictors of 
attendance for breast screening in inner London. J Epidemiol Community Health 
1994;48:65-73. 
8. Drescher C, Holt SK, Andersen MR, Anderson G, Urban N. Reported ovarian cancer 
screening among a population-based sample in Washington State. Obstet Gynecol 
2000;96:70-4. 
9. Hay JL, Buckley TR, Ostroff JS. The role of cancer worry in cancer screening: a 
theoretical and empirical review of the literature. Psychooncology 2005;14:517-34. 
10. Consedine NS, Magai C, Krivoshekova YS, Ryzewicz L, Neugut AI. Fear, anxiety, 
worry, and breast cancer screening behavior: a critical review. Cancer Epidemiol Biomarkers 
Prev 2004;13:501-10. 
11. Öhman A. Fear and anxiety: overlaps and dissociations. In: Lewis M, Haviland-Jones 
JM, Barrett LF, editors. Handbook of emotions. 3rd ed. ed. New York, NY: The Guilford 
Press; 2008. p. 709-29. 
12. McCaul KD, Reid PA, Rathge RW, Martinson B. Does concern about breast cancer 
inhibit or promote breast cancer screening? Basic Appl Soc Psychol 1996;18:183-94. 
13. Clemow L, Costanza ME, Haddad WP, Luckmann R, White MJ, Klaus D, et al. 
Underutilizers of mammography screening today: characteristics of women planning, 
undecided about, and not planning a mammogram. Ann Behav Med 2000;22:80-8. 
14. Consedine NS, Adjei BA, Ramirez PM, McKiernan JM. An object lesson: Source 
determines the relations that trait anxiety, prostate cancer worry, and screening fear hold 
with prostate screening frequency. Cancer Epidemiol Biomarkers Prev 2008;17:1631-9. 
8 
 
15. Wong RK, Wong ML, Chan YH, Feng Z, Wai CT, Yeoh KG. Gender differences in 
predictors of colorectal cancer screening uptake: a national cross sectional study based on 
the health belief model. BMC Public Health 2013;13:677-88. 
16. Jandorf L, Ellison J, Villagra C, Winkel G, Varela A, Quintero-Canetti Z, et al. 
Understanding the barriers and facilitators of colorectal cancer screening among low income 
immigrant hispanics. J Immigr Minor Health 2010;12:462-9. 
17. Atkin WS, Edwards R, Wardle J, Northover JM, Sutton S, Hart AR, et al. Design of a 
multicentre randomised trial to evaluate flexible sigmoidoscopy in colorectal cancer 
screening. J Med Screen 2001;8:137-44. 
18. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al. 
Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre 
randomised controlled trial. Lancet 2010;375:1624-33. 
19. Grundy E, Holt G. The socioeconomic status of older adults: how should we measure 
it in studies of health inequalities? J Epidemiol Community Health 2001;55:895-904. 
20. Vrinten C, van Jaarsveld CH, Waller J, von Wagner C, Wardle J. The structure and 
demographic correlates of cancer fear. BMC Cancer 2014;14:597. 
21. Sheeran P. Intention—behavior relations: A conceptual and empirical review. Eur 
Rev Soc Psychol 2002;12:1-36. 
22. Azaiza F, Cohen M. Colorectal cancer screening, intentions, and predictors in Jewish 
and Arab Israelis: a population-based study. Health Educ Behav 2008;35:478-93. 
23. Waters EA, Hay JL, Orom H, Kiviniemi MT, Drake BF. “Don’t Know” Responses to 
Risk Perception Measures Implications for Underserved Populations. Med Decis Making 
2013;33:271-81. 
 
  
9 
 
Table 1. Characteristics of Sample 1 and Sample 2. 
 Sample 1 
N (%)* 
Sample 2 
N (%)* 
Sample size 7,327 
(100.0) 
1,920 
(100.0) 
Age in years (mean, 
SD) 
60.0 (2.9) 60.0 (2.9) 
Gender 
   Male 
   Female 
 
3,351 (45.7) 
3,976 (54.3) 
 
916 (47.7) 
1,004 (52.3) 
Educational 
qualifications 
   Yes 
   No 
   Missing 
 
2,522 (34.4) 
4,382 (59.8) 
423 (5.8) 
 
706 (36.8) 
1,109 (57.8) 
105 (5.5) 
Ethnicity 
   White 
   Not White 
   Missing 
 
6,774 (92.5) 
325 (4.4) 
228 (3.1) 
 
1,783 (92.9) 
81 (4.2) 
56 (2.9) 
Marital status 
   Married or cohabiting 
   Not married or 
cohabiting 
   Missing 
 
5,326 (72.7) 
1,872 (25.5) 
129 (1.8) 
 
1,443 (75.2) 
443 (23.1) 
34 (1.8) 
Greatest health fear 
   Strongly disagree 
   Disagree 
   Not sure 
   Agree 
   Strongly agree 
 
232 (3.2) 
1,391 (19.0) 
1,410 (19.2) 
3,156 (43.1) 
1,138 (15.5) 
 
47 (2.4) 
323 (16.8) 
326 (17.0) 
882 (45.9) 
342 (17.8) 
Worry 
   Strongly disagree 
   Disagree 
   Not sure 
   Agree 
   Strongly agree 
 
842 (11.5) 
3,578 (48.4) 
1,048 (14.3) 
1,511 (20.6) 
348 (4.7) 
 
186 (9.7) 
929 (48.4) 
270 (14.1) 
442 (23.0) 
93 (4.8) 
Discomfort 
   Strongly disagree 
   Disagree 
   Not sure 
   Agree 
   Strongly agree 
 
277 (3.8) 
1,931 (26.4) 
1,265 (17.3) 
3,315 (45.2) 
539 (7.4) 
 
74 (3.9) 
517 (26.9) 
340 (17.7) 
857 (44.6) 
132 (6.9) 
*Unless otherwise stated, values in this column represent absolute numbers and 
percentages of the sample. 
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Table 2. Spearman’s correlations between the cancer fear indicators for Sample 1 and 2. 
 
  Worry Discomfort 
Sample 1 
n=7,327 
Greatest health fear .42 .38 
Worry  .36 
Sample 2  
n=1,920 
Greatest health fear .42 .36 
Worry  .39 
All correlations are significant at p<.001 
 
Table 3. Percentages, adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for 
intending to attend FS screening (‘yes probably’/‘yes definitely’), by each cancer fear 
indicator (Sample 1; n=7,327). 
 
 Intending to 
attend N (%) 
Adjusted 
OR† (95% CI) 
Sample 1 5,996 (81.8) - 
Greatest health 
fear 
   (Strongly) 
disagree 
   Not sure 
   (Strongly) agree 
 
1,207 (74.4) 
1,108 (78.6) 
3,681 (85.7) 
 
Ref 
1.30 (1.09-1.54)* 
2.32 (2.01-2.69)* 
Worry 
   (Strongly) 
disagree 
   Not sure 
   (Strongly) agree 
 
3,481 (78.8) 
870    (83.0) 
1,645 (88.5) 
 
Ref 
1.38 (1.15-1.65)* 
2.34 (1.99-2.75)* 
Discomfort 
   (Strongly) 
disagree 
   Not sure 
   (Strongly) agree 
 
1,834 (83.1) 
1,076 (85.1) 
3,086 (80.1) 
 
Ref 
1.22 (1.00-1.47) 
0.88 (0.76-1.01) 
*p<.01 
† Adjusted for age, gender, education, ethnicity, and marital status. 
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Table 4. Percentages, adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for 
attending FS screening, by each cancer fear indicator (Sample 2; n=1,920). 
 
 Attended N (%) Adjusted 
OR† (95% CI) 
Sample 2 1,359 (70.8) - 
Greatest health 
fear 
   (Strongly) 
disagree 
   Not sure 
   (Strongly) agree 
 
267 (72.2) 
238 (73.0) 
854 (69.8) 
 
Ref 
1.10 (0.78-1.55) 
1.06 (0.81-1.38) 
Worry 
   (Strongly) 
disagree 
   Not sure 
   (Strongly) agree 
 
807 (72.4) 
202 (74.8) 
350 (65.4) 
 
Ref 
1.19 (0.87-1.63) 
0.83 (0.66-1.05) 
Discomfort 
   (Strongly) 
disagree 
   Not sure 
   (Strongly) agree 
 
456 (77.2) 
230 (67.6) 
673 (68.0) 
 
Ref 
0.68 (0.50-0.92)§ 
0.72 (0.56-0.91)* 
*p<.01 
§ p=.012 
† Adjusted for age, gender, education, ethnicity, and marital status. 
 
Figure legends 
Figure 1. Flow diagram of study inclusion 
